Black Diamond Therapeutics Reports Officer/Director Changes
Ticker: BDTX · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1701541
| Field | Detail |
|---|---|
| Company | Black Diamond Therapeutics, Inc. (BDTX) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-change, corporate-governance, compensation
TL;DR
**Black Diamond Therapeutics just reported executive changes, watch for strategic shifts.**
AI Summary
Black Diamond Therapeutics, Inc. filed an 8-K on January 18, 2024, reporting an event that occurred on January 17, 2024. The filing indicates a change in directors or officers and/or compensatory arrangements for certain officers. This matters to investors because changes in leadership or executive compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in executive leadership or compensation can influence a company's strategic direction and operational efficiency, directly affecting its stock valuation.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of the changes are not provided in this summary, making the impact unclear.
Analyst Insight
Investors should look for subsequent filings or press releases from Black Diamond Therapeutics, Inc. that provide specific details about the reported changes in directors, officers, or compensatory arrangements to assess the potential impact on the company's future.
Key Players & Entities
- Black Diamond Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 17, 2024 (date) — date of the earliest event reported
- January 18, 2024 (date) — date the 8-K was filed
- 001-39200 (other) — SEC File Number for Black Diamond Therapeutics, Inc.
- Delaware (other) — State of incorporation for Black Diamond Therapeutics, Inc.
FAQ
What specific event did Black Diamond Therapeutics, Inc. report in this 8-K filing?
Black Diamond Therapeutics, Inc. reported an event concerning 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as per Item Information in the filing.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 17, 2024, as stated under 'Date of Report (Date of earliest event reported): January 17, 2024'.
What is the SEC File Number for Black Diamond Therapeutics, Inc.?
The SEC File Number for Black Diamond Therapeutics, Inc. is 001-39200, as indicated in the filing.
What is the business address of Black Diamond Therapeutics, Inc. as listed in the filing?
The business address of Black Diamond Therapeutics, Inc. is One Main Street, 14th Floor, Cambridge, Massachusetts, 02141, according to the filing.
Under which section of the Securities Exchange Act of 1934 was this current report filed?
This current report was filed 'Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934'.
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-18 16:04:40
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share BDTX The Nasdaq G
Filing Documents
- tm243561d1_8k.htm (8-K) — 26KB
- 0001104659-24-004802.txt ( ) — 196KB
- bdtx-20240117.xsd (EX-101.SCH) — 3KB
- bdtx-20240117_lab.xml (EX-101.LAB) — 33KB
- bdtx-20240117_pre.xml (EX-101.PRE) — 22KB
- tm243561d1_8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. On January 17, 2024, Rajeev Shah notified Black Diamond Therapeutics, Inc. (the "Company") of his intent to resign from the Company's Board of Directors (the "Board"), including his position as a member of the Audit Committee of the Board, effective immediately. Mr. Shah served as a member of the Board since December 2018. Mr. Shah's decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BLACK DIAMOND THERAPEUTICS, INC. Date: January 18, 2024 By: /s/ Brent Hatzis-Schoch Name: Brent Hatzis-Schoch Title: Chief Operating Officer and General Counsel